Clover Biopharmaceuticals, Ltd.
HKSE: 2197.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Joshua G. Liang
- Employees
- 300
- Headquarters
- Shanghai, China
- IPO year
- 2021
- Market cap
- HK$3.5B
- Website
- https://www.cloverbiopharma.com
Loading 2197…
Loading profile data…Frequently asked questions about 2197
What does Clover Biopharmaceuticals, Ltd. (2197.HK) do?
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SC...
Where does 2197.HK trade?
Clover Biopharmaceuticals, Ltd. (2197.HK) trades on the Hong Kong Stock Exchange.
What sector is 2197.HK in?
Clover Biopharmaceuticals, Ltd. (2197.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Clover Biopharmaceuticals, Ltd.?
Joshua G. Liang is the chief executive officer of Clover Biopharmaceuticals, Ltd. (2197.HK).
Where is Clover Biopharmaceuticals, Ltd. headquartered?
Clover Biopharmaceuticals, Ltd. is headquartered in China.
Does 2197.HK pay a dividend?
Clover Biopharmaceuticals, Ltd. (2197.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2197.HK go public?
Clover Biopharmaceuticals, Ltd. (2197.HK) completed its initial public offering in 2021.